# EDGAR Filing Document

**Accession Number:** 0002032966
**File Stem:** 0001213900-25-070009
**Filing Date:** 2025-7
**Character Count:** 12713
**Document Hash:** 93358a4fe9f4f7d768c376db7918bdaf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-070009.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0001213900-25-070009

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250731

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACUREN CORP
- **CENTRAL INDEX KEY:** 0002032966
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-BUSINESS SERVICES, NEC [7389]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42524
- **FILM NUMBER:** 251172044

**BUSINESS ADDRESS:**
- **STREET 1:** 14434 MEDICAL COMPLEX DRIVE
- **STREET 2:** #100
- **CITY:** TOMBALL
- **STATE:** TX
- **ZIP:** 77377
- **BUSINESS PHONE:** 800-218-7450

**MAIL ADDRESS:**
- **STREET 1:** 14434 MEDICAL COMPLEX DRIVE
- **STREET 2:** #100
- **CITY:** TOMBALL
- **STATE:** TX
- **ZIP:** 77377

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported) July 31, 2025**

**Acuren Corporation**

**(Exact Name of Registrant as Specified in its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42524** | **66-1076867** |
| **(State or Other Jurisdiction<br> of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br> Identification No.)** |

---

---

| | |
|:---|:---|
| **14434 Medical Complex Drive, Suite 100<br> Tomball, TX** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**77377** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(Address of Principal Executive Offices)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(Zip Code)** |

---

**Registrant's telephone number, including area code: (800) 218-7450**

**(Former name or former address, if changed since last report) Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.0001 per share** | **TIC** | **The New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☒ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On July 31, 2025, Acuren Corporation (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders voted on the (i) approval of the issuance of shares of common stock, par value $0.0001 per share of the Company (the "Common Stock"), to stockholders of NV5 Global, Inc. ("NV5") in connection with the Agreement and Plan of Merger dated May 14, 2025, by and among the Company, NV5, and certain direct, wholly owned subsidiaries of the Company (Proposal 1), (ii) election of eight director nominees (Proposal 2), (iii) ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered accounting firm for the 2025 fiscal year (Proposal 3), and (iv) approval of the Company's 2025 Employee Stock Purchase Plan (Proposal 4). The proposal to approve the adjournment of the Annual Meeting was not voted on at the Special Meeting because there were sufficient votes to approve Proposal 1.

The results of the votes are set forth below.

**<u>Proposal 1—Approval of the Issuance of Shares of the Company to Stockholders of NV5</u>**

The stockholders approved the issuance of shares of Common Stock to stockholders of NV5 in connection with the Agreement and Plan of Merger.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** |
|  | 94157704 |  | 6285 |  | 24153 |

---

**<u>Proposal 2—Election of Directors</u>**

The stockholders voted in favor of the election of the following director nominees as directors for a term of office expiring at the Company's 2026 Annual Meeting of Stockholders and, in each case, until his or her successor is duly elected and qualified.

---

| | | | |
|:---|:---|:---|:---|
|  | **For** | **Against** | **Abstain** |
| Sir Martin E. Franklin | 91027329 | 3149584 | 11229 |
| Robert A. E. Franklin | 93192053 | 983560 | 12529 |
| Antoinette C. Bush | 94074314 | 78105 | 35723 |
| Rory Cullinan | 94148401 | 28418 | 11323 |
| Elizabeth Meloy Hepding | 94094716 | 57668 | 35758 |
| Peter Hochfelder | 94138229 | 38290 | 11623 |
| James E. Lillie | 90173481 | 4003337 | 11324 |
| Talman Pizzey | 94087506 | 89313 | 11323 |

---

**<u>Proposal 3—Ratification of Appointment of Independent Registered Public Accounting Firm</u>**

The stockholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** |
|  | 94155216 |  | 21803 |  | 11123 |

---

**<u>Proposal 4—Approval of the Company's 2025 Employee Stock Purchase Plan</u>**

The stockholders approved the 2025 Employee Stock Purchase Plan.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** |
|  | 94139694 |  | 34925 |  | 13523 |

---

**Item 7.01 Regulation FD**

Acuren issued a press release on July 31, 2025, announcing the voting results of the Annual Meeting, which is furnished hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, dated July 31, 2025.](ea025106701ex99-1_acuren.htm) |
| 104 | Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **Acuren Corporation** | **Acuren Corporation** |
| By: | /s/ Kristin Schultes |
| Name: | Kristin Schultes |
| Title: | Chief Financial Officer |

---

Date: July 31, 2025

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Acuren Corporation Stockholders Approve Stock Issuance in Merger with NV5 Global, Inc.**

July 31, 2025

TOMBALL, Texas: Acuren Corporation (NYSE: TIC) (the "**Company**" or "**Acuren**") announced today that its stockholders voted to approve the issuance of shares of Acuren common stock to stockholders of NV5 Global, Inc. ("**NV5**"), in connection with the previously announced Agreement and Plan of Merger (the "**Merger Agreement**"), dated as of May 14, 2025, by and among Acuren, NV5, Ryder Merger Sub I, Inc. and Ryder Merger Sub II, Inc. ("**Acuren Stock Issuance Proposal**"). The vote occurred at Acuren's annual meeting of stockholders (the "**Meeting**") that was held on July 31, 2025, at 9:30 AM ET.

Approval of the Acuren Stock Issuance Proposal required the affirmative vote of a majority of the votes cast at the Meeting. 99.99% of the votes cast at the Meeting voted in favor of the Acuren Stock Issuance Proposal.

Tal Pizzey, Chief Executive Officer of Acuren, said, "We thank our stockholders for their support for the business combination with NV5, and with this milestone now complete, we look forward to moving expeditiously toward closing."

The transaction is expected to close in August 2025, subject to the receipt of certain regulatory approvals.

In addition to the Acuren Stock Issuance Proposal, Acuren's stockholders passed all other resolutions put before them, including the election of all directors nominated for reelection.

**<u>About Acuren</u>**

Acuren is a leading provider of critical asset integrity services. The company operates primarily in North America serving a broad range of industrial markets. It provides these essential and often compliance-mandated (often at customer locations) services in the industrial space and is focused on the recurring maintenance needs of its customers. The work Acuren does fits in the service category referred to as Testing, Inspection, Certification, and Compliance (TICC) including Nondestructive Testing (NDT) in the field and the laboratory and in-lab destructive testing capabilities. More information can be found at https://www.acuren.com/.

**<u>Cautionary Note Regarding Forward-Looking Statements</u>**

Certain statements in this press release are "forward-looking" statements based on assumptions currently believed to be valid. Forward-looking statements are all statements other than statements of historical facts. The words "anticipate," "believe," "ensure," "expect," "if," "intend," "estimate," "probable," "project," "forecasts," "predict," "outlook," "aim," "will," "could," "should," "would," "potential," "may," "might," "anticipate," "likely" "plan," "positioned," "strategy," and similar expressions or other words of similar meaning, and the negatives thereof, are intended to identify forward-looking statements. Specific forward-looking statements in this press release include statements regarding the Annual Meeting and the expected closing of the merger with NV5. The forward-looking statements are intended to be subject to the safe harbor provided by Section 27A of the Securities Act, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995.

These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the risk that a condition to closing of the Transactions may not be satisfied, that either party may terminate the Merger Agreement or that the Closing might be delayed or not occur at all. Additional factors that could cause results to differ materially from those described above can be found in NV5's Annual Report on Form 10-K for the year ended December 28, 2024, as amended, which is on file with the SEC and available from NV5's website at www.nv5.com under the "Investor Relations" tab, and in other documents NV5 files with the SEC; and in Acuren's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the SEC and available from Acuren' website at www.acuren.com under the "Investor Relations" tab, and in other documents Acuren files with the SEC.

All forward-looking statements speak only as of the date they are made and are based on information available at that time. Acuren assumes no obligation to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements.

**<u>Investor Contact:</u>**

Andrew Shen<br> Director of Investor Relations<br> Email: IR@acuren.com

Source: Acuren Corporation